ArticleJournal of translational medicine2026
A comprehensive plasma-based approach to thromboinflammation in bladder cancer: integrating lipidomics, thrombin generation, and NETosis biomarkers.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipid metabolism reprogramming is a hallmark of cancer, yet its systemic manifestations and functional implications in bladder cancer (BC) remain poorly understood. This study aimed to identify plasma lipidomic profiles with diagnostic, staging, and prognostic value in BC, and to explore their associations with thromboinflammatory mechanisms, particularly NETosis and thrombin generation.
methodsPlasma lipidomics was characterized by ultra-high-performance liquid chromatography high-resolution mass spectrometry from 87 BC patients (non-muscle-invasive BC, NMIBC, and muscle-invasive BC, MIBC) and 30 controls. NETosis markers, active DNaseI concentration, C-reactive protein, fibrinogen, IL-6, prothrombin F1+2, thrombin-antithrombin (TAT) complexes, and thrombin generation tests (TGT) were assessed in parallel. Statistical analyses in R included PCA, ROC curve analysis, elastic net penalized logistic regression, Cox regression, natural cubic spline modeling for survival analyses, and pathway enrichment analyses.
resultsBC patients exhibited increased total lipid load and distinct lipidomic signatures. Phosphatidylcholine (PC) levels decreased with disease severity and were independently associated with poor overall survival (up to 85% reduction in MIBC). Multivariable elastic net models integrating lipidomic and clinical variables achieved high diagnostic accuracy for discriminating BC patients from controls (AUC = 0.943) and for distinguishing MIBC from NMIBC (AUC = 0.860). BC patients displayed increased NETosis, inflammation, and thrombin formation, while decreased active DNaseI. Potentially diagnostic lipids correlated with NETosis, inflammatory markers and TAT, and inversely with active DNaseI and TGT parameters. Given the cross-sectional and observational design, these findings should be interpreted as hypothesis-generating and do not allow causal inference.
conclusionsPlasma lipidomic profiling identifies biomarkers with diagnostic and prognostic potential in BC and reveals associations with NETosis, active DNaseI dysfunction, and thrombin generation. While causality cannot be inferred from this exploratory study, these findings support lipidomics as a minimally invasive tool for BC stratification and as a window into cancer-associated immunothrombosis, providing a rationale for future longitudinal and mechanistic studies targeting lipid-neutrophil interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.